At a glance
An ACTH-related peptide explored in intranasal neurological research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source now uses nasal preparation and actuator tables. Findings from a documented nasal formulation should not be transferred to an injection schedule.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Semax.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 4 source tables
Semax 5 mg Nasal Spray Calculations
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 1,000 mcg/mL | 100 mcg50 nominal sprays |
| 10.0 mL | About 7.0 mL | 500 mcg/mL | 50 mcg100 nominal sprays |
Both options begin with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume. Calculation basis: Each row uses the full 5 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal spray counts are calculated before priming and normal residual hold-up.
Research Amount to Spray Equivalents
| Research Amount | 5 mL Option100 mcg per Spray | 10 mL Option50 mcg per Spray |
|---|---|---|
| 200 mcg | 2 sprays | 4 sprays |
| 300 mcg | 3 sprays | 6 sprays |
| 400 mcg | 4 sprays | 8 sprays |
| 500 mcg | 5 sprays | 10 sprays |
These rows are concentration conversions. They do not turn one study amount into a universal schedule. Use the measured final volume and verified actuator output in every calculation. Bottle capacity alone does not establish the final volume or the amount delivered per spray.
Published Human Intranasal Semax Research
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Kaplan et al., 1996[1] | Healthy volunteers in operator and EEG experiments | Experiments included 0.25 mg and 1 mg exposures. The operator experiment reported 1 mg in 0.4 mL physiological solution. |
| Lebedeva et al., 2018[2] | Healthy volunteer fMRI study | One 1.2 mg exposure using a 1% solution, with 60 microliters placed into each nostril. |
| Gusev et al., 2018[3] | Condition-specific post-stroke research | 6,000 mcg per day for 10 days, followed by a second 10-day course after a 20-day interval. |
| Official 0.1% Semax instructions[4] | Registered intranasal drop formulation | 1 mg/mL in purified water with methylparaben. Each 0.05 mL drop contained 50 mcg. |
Human Semax research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable. The 5 mL calculation above also produces 1 mg/mL, which matches the concentration of the registered 0.1% drop formulation. The device and formulation are still different, so concentration equivalence does not establish identical delivery, stability, or dosing.
Core Formula
| Verified Actuator Output | 5 mL Option1,000 mcg/mL | 10 mL Option500 mcg/mL |
|---|---|---|
| 0.05 mL | 50 mcg | 25 mcg |
| 0.10 mL | 100 mcg | 50 mcg |
| 0.13 mL | 130 mcg | 65 mcg |
mcg per spray = (5,000 mcg / final volume in mL) x verified mL per spray nominal sprays = final volume in mL / verified mL per spray
Additional schedule context & duration
Quick reference for the intranasal Semax 5 mg calculation.
- Human research route: Intranasal drops or solution.
- Peptide amount: 5,000 mcg total in the vial.
- 5 mL option: 1,000 mcg/mL and 100 mcg per verified 0.10 mL spray.
- 10 mL option: 500 mcg/mL and 50 mcg per verified 0.10 mL spray.
- Final-volume rule: Bring the transferred solution to an exact measured final volume.
Preparation
How to Prepare the 5 mL or 10 mL Research Bottle
- Confirm the 5 mg vial, selected sterile research vehicle, actuator bottle capacity, and documented pump output.
- Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique.
- Gently swirl until the contents are dissolved. Do not shake.
- Transfer the complete 3.0 mL solution into a sterile 5 mL or 10 mL nasal actuator bottle.
- Add enough vehicle to reach a measured final volume of exactly 5.0 mL or 10.0 mL. The theoretical additions are approximately 2.0 mL and 7.0 mL.
- Secure the pump and label the bottle with the peptide amount, final volume, concentration, pump output, and preparation date.
- Prime the pump according to the actuator instructions and record the priming sprays in the research log.
Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. Kaplan and colleagues reported physiological solution in one human experiment. The registered 0.1% Semax product used purified water with methylparaben, so the saline example is not the same as the registered multidose formulation[1][4].
Storage Instructions
Storage depends on the complete formulation, container, and handling method.
- Registered 0.1% product: Protected from light, stored at no more than 10 degrees C, and not frozen[4].
- Custom research preparation: Use formulation-specific stability and microbiological controls.
- Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.
- Handling: Keep the cap secured and minimize unnecessary warming and light exposure.
Nasal Actuator Technique
Use a standardized device procedure so the recorded amount remains consistent across research observations.
- Inspect the labeled concentration and confirm the actuator output before use.
- Prime or reprime the pump according to the manufacturer instructions.
- Keep the bottle in the specified orientation and use one complete, smooth stroke.
- Record each actuation immediately, including priming sprays.
- Wipe the nozzle with a clean material appropriate for the device and replace the cap.
- Return the bottle to its documented storage condition after the research procedure.
Materials & quantity planning
Source materials checklist · 5 mg
Use one complete set of measured and sterile research supplies for each prepared Semax 5 mg nasal bottle.
- Semax 5 mg research vial: One vial per prepared bottle. The product gallery below links to the existing Semax 5 mg supplier page.
- Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
- Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
- Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
- Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
- Sterile transfer needle: Required when the peptide vial uses a rubber septum.
- Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
- Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
- Storage materials: Light-protective refrigerated storage appropriate to the validated formulation.
- Sharps container: Use when transfer needles are part of the preparation workflow.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
Continue exploring
Related topics are not interchangeable compounds or formulations.